Patient and physician treatment preferences in atrial fibrillation2018-02-16T14:46:03+00:00

Patient and physician treatment preferences in atrial fibrillation

“There was a lack of evidence on whether physicians were prescribing anticoagulant treatments with attribute profiles most valued by patients.”

Challenge

Numerous treatment options are available for nonvalvular atrial fibrillation (NVAF) patients, each offering a different combination of associated attributes, such as stroke risk, bleeding risk, and convenience. There was a lack of evidence on whether physicians were prescribing anticoagulant treatments with attribute profiles most valued by patients.

Response

Conduct a survey of physicians and patients using discrete choice experiment methods to understand the value these stakeholders place on different treatment attributes and the alignment between physicians and patients.

Results

Surveying approximately 200 patients and 200 physicians, PHE assessed how much in monthly copayments participants would be willing to trade for changes in different treatment attributes. The results demonstrated that patients preferred the attribute profile of apixaban to other novel oral anticoagulants.  Further, we found that moving from current prescribing practices to ones preferred by patients would reduce the number of strokes in the US by 7540 (8.3%) and would reduce the number of major bleeding events by 14,249 (7.8%) among patients with NVAF.

Impact

Within a crowded market of new anticoagulant therapies, the results of the study provided evidence on the advantages of a specific treatment profile, like that of apixaban, that offers lower bleeding risk, lower stroke risk, and greater convenience. The results were published in Value in Health, lending further credibility to the study results.

PHE’s research demonstrated the value of apixaban’s treatment profile compared with that of other anticoagulant therapies.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK